Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × OTHER × Clonal Evolution × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1

Interventions

Cyclophosphamide 851 Radiotherapy 763 Cisplatin 657 Gemcitabine 583 Docetaxel 538 Carboplatin 538 Paclitaxel 529 Bevacizumab 513 Fluorouracil 452 Rituximab 412 Oxaliplatin 405 Capecitabine 400 Surveys and Questionnaires 391 Dexamethasone 388 Doxorubicin 381 Etoposide 367 Irinotecan 351 Cytarabine 333 Filgrastim 330 pembrolizumab 277 Leucovorin 277 Melphalan 266 fludarabine phosphate 261 Magnetic Resonance Spectroscopy 259 Nivolumab 254 Blood Specimen Collection 251 Lenalidomide 244 Peripheral Blood Stem Cell Transplantation 242 Methotrexate 239 Cetuximab 236

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03521596 2025-11-18

FIL_BIOWM

Fondazione Italiana Linfomi - ETS

Waldenstrom Macroglobulinemia, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡